Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05107882 · ClinicalTrials.gov registry record
Optina Diagnostics' Cerebral ß-Amyloid Status (CAS) Test
A clinical trial, sponsored by Optina Diagnostics.
- Completed
- Registry status
- 466
- Enrollment target
NCT05107882 is a clinical trial that has completed, run by Optina Diagnostics. The registered enrollment target is 466 participants.
The verdict
NCT05107882 has completed, sponsored by Optina Diagnostics.
- COMPLETED
- Registry status
- 466 participants
- Enrollment target
Study Summary
This observational, cross-sectional study is designed to validate a novel diagnostic test for the detection of phenotypic changes in the retina that correlate with likely PET amyloid status (negative or positive), to aid in the evaluation of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline. The CAS test is an adjunct to other diagnostic evaluations, and is indicated for use with the Optina Diagnostics' MHRC (K200254).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 466 participants |
| Start Date | 2022-06-07 |
| Est. Completion | 2024-07-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05107882
The ClinicalTrials.gov registry entry for NCT05107882 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 466 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Optina Diagnostics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05107882 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05107882 about?
NCT05107882 is a clinical study titled "Optina Diagnostics' Cerebral ß-Amyloid Status (CAS) Test". This observational, cross-sectional study is designed to validate a novel diagnostic test for the detection of phenotypic changes in the retina that correlate with likely PET amyloid status (negative or positive), to aid in the evaluation of adult patients with cognitive impairment who are being eva...
What is the current status of trial NCT05107882?
This trial is currently completed. The enrollment target is 466 participants. The study started on 2022-06-07. Estimated completion is 2024-07-25.
Who is sponsoring clinical trial NCT05107882?
This trial is sponsored by Optina Diagnostics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.